Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 4/20 | 0.50 |
| ▸ | HHAT | Q5VTY9 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23947745 | 0.86 | LHCGR (0.48) | LHCGRHHATNPSR1L3MBTL1 | |
| SCHEMBL29763691 | 0.80 | HHAT (0.40) | LHCGRHHAT | |
| SCHEMBL23947759 | 0.80 | HHAT (0.40) | LHCGRHHAT | |
| SCHEMBL2308598 | 0.70 | LHCGR (0.52) | LHCGRHHATL3MBTL1 | |
| SCHEMBL2303975 | 0.70 | LHCGR (0.52) | LHCGRHHATSMN1; SMN2 | |
| SCHEMBL2307398 | 0.70 | LHCGR (0.52) | LHCGRHHATSMN1; SMN2LMNA | |
| SCHEMBL2311930 | 0.70 | LHCGR (0.51) | LHCGRHHATSMN1; SMN2 | |
| SCHEMBL2307742 | 0.70 | LHCGR (0.51) | LHCGRHHATLMNA | |
| SCHEMBL23947746 | 0.69 | HHAT (0.46) | HHAT | |
| SCHEMBL29763656 | 0.69 | HHAT (0.46) | HHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533339-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240173291-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| US-11877999-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-23 | — | — | US | disclosed |
| US-11628158-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| WO-2021212010-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | LHCGR 3029/4885HHAT 2179/4885NPSR1 4713/4885 |
| US-11877999-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | TP53, EIF2AK2, POLI | LHCGR 3029/4885HHAT 2179/4885NPSR1 4713/4885 |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | LHCGR 3029/4885HHAT 2179/4885NPSR1 4713/4885 |
| US-12533339-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | CCND3, CCND1, TPD52L2 | LHCGR 630/4885HHAT 2716/4885NPSR1 3458/4885 |
| US-20240173291-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | LHCGR 3029/4885HHAT 2179/4885NPSR1 4713/4885 |
| US-11628158-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | TP53, EIF2AK2, POLI | LHCGR 3029/4885HHAT 2179/4885NPSR1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.